Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites

Molecular Cancer Research

Volumn 3, Issue 3, 2005, Pages 130-138

  Ishii, Hideshi ^a   Mimori, Koshi ^b   Inageta, Taeko ^a   Murakumo, Yoshiki ^c   Vecchione, Andrea ^d   Mori, Masaki ^b   Furukawa, Yusuke ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATR PROTEIN; FRAGILE HISTIDINE TRIAD PROTEIN; MESSENGER RNA; PROTEIN DERIVATIVE; THYMIDINE; UNCLASSIFIED DRUG; WWOX PROTEIN;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHROMOSOME FRAGILE SITE; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; FIBROBLAST; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC STABILITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; ULTRAVIOLET RADIATION;

ACID ANHYDRIDE HYDROLASES; ANIMALS; BLOTTING, NORTHERN; CELL CYCLE; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME FRAGILE SITES; CHROMOSOME FRAGILITY; DNA; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, RADIATION; FIBROBLASTS; FLOW CYTOMETRY; G1 PHASE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; NEOPLASM PROTEINS; NEOPLASMS; OXIDOREDUCTASES; RNA; S PHASE; TIME FACTORS; TRANSFECTION; ULTRAVIOLET RAYS;

ATAXIA; ATAXIA TELANGIECTASIA; MURINAE;

EID: 17144405305     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-04-0209     Document Type: Article

References (45)

1. Glover TW, Berger C, Coyle J, Echo B. DNA polymerase α inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet 1984;67:136-42.
2. Yunis JJ, Soreng AL. Constitutive fragile sites and cancer. Science 1984;226:1199-204.
3. Huebner K, Croce CM. FRA3B and other common fragile sites: the weakest link. Nat Rev Cancer 2001;1:214-21.
4. Smith DI, Huang H, Wang L. Common fragile sites and cancer. Int J Oncol 1998;12:187-96.
5. Casper AM, Nghiem P, Arlt MF, Glover TW. ATR regulates fragile site stability. Cell 2002;111:779-89.
6. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004;73:39-85.
7. Bednarek AK, Keck-Waggoner CL, Daniel RL, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 2001;61:8068-73.
8. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000;60:2140-5.
9. Sozzi G, Huebner K, Croce CM. FHIT in human cancer. Adv Cancer Res 1998;74:141-66.
10. Kuroki T, Yendamuri S, Trapasso F, et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 2004;10:2459-65.
11. Ishii H, Vecchione A, Furukawa Y, et al. Expression of FRA16D/WWOX and FRA3B/FHIT Genes in Hematopoietic Malignancies. Mol Cancer Res 2003;1:940-7.
12. Rosell R, Monzo M, O'Brate A, Taron M. Translational oncogenomics: toward rational therapeutic decision-making. Curr Opin Oncol 2002;14:171-9.
13. Ishii H, Furukawa Y. Alterations of common chromosome fragile sites in hematopoietic malignancies. Int J Hematol 2004;79:238-42.
14. Ishii H, Dumon KR, Vecchione A, et al. Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies. JAMA 2001;286:2441-9.
15. Chang NS, Doherty J, Ensign A. JNK1 Physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J Biol Chem 2003;278:9195-202.
16. de Gruijl FR. Skin cancer and solar UV radiation. Eur J Cancer 1999;35:2003-9.
17. Matsumura Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol 2004;195:298-308.
18. Zanesi N, Croce CM. Fragile histidine triad gene and skin cancer. Eur J Dermatol 2001;11:401-4.
19. Ishii H, Mimori K, Vecchione A, et al. Effect of exogenous E2F-1 on the expression of common chromosome fragile site genes, FHIT and WWOX. Biochem Biophys Res Commun 2004;316:1088-93.
20. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
21. 1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol 2001;13:738-47.
22. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993;365:349-52.
23. Dalton S. Cell cycle regulation of the human cdc2 gene. EMBO J 1992;11:1797-804.
24. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A 1995;92:12146-50.
25. Schulze A, Zerfass K, Spitkovsky D, et al. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc Natl Acad Sci U S A 1995;92:11264-8.
26. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 1994;8:1514-25.
27. Kowalik TF, DeGregori J, Schwarz JK, Nevins JR. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol 1995;69:2491-500.
28. Field SJ, Tsai FY, Kuo F, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996;85:549-61.
29. Furukawa Y, Nishimura N, Furukawa Y, et al. Apaf-1 is a mediator of E2F-I-induced apoptosis. J Biol Chem 2002;277:39760-8.
30. Nahle Z, Polakoff J, Davuluri RV, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 2002;4:859-64.
31. Yang HL, Dong YB, Elliott MJ, et al. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells. Clin Cancer Res 1999;5:2242-50.
32. Yang HL, Dong YB, Elliott MJ, Liu TJ, McMasters KM. Caspase activation and changes in Bcl-2 family member protein expression associated with E2F-1-mediated apoptosis in human esophageal cancer cells. Clin Cancer Res 2000;6:1579-89.
33. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996;85:537-48.
34. Pan H, Yin C, Dyson NJ, Harlow E, Yamasaki L, Van Dyke T. Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. Mol Cell 1998;2:283-92.
35. Wikonkal NM, Remenyik E, Knezevic D, et al. Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice. Nat Cell Biol 2003;5:655-60.
36. Ottey M, Han SY, Druck T, et al. Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant. Br J Cancer 2004;91:1669-77.
37. Dumon KR, Ishii H, Fong LYY, et al. FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci U S A 2001;98:3346-51.
38. Ishii H, Zapesi N, Vecchione A, et al. Prevention and regression of upper gastric cancer in mice by FHIT gene therapy. FASEB J 2003;17:1768-70.
39. Inoue H, Ishii H, Alder H, et al. Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proc Natl Acad Sci U S A 1997;94:14584-9.
40. Mimori K, Druck T, Inoue H, et al. Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. Proc Natl Acad Sci U S A 1999;96:7456-61.
41. Matsuyama A, Shiraishi T, Trapasso F, et al. Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2: evolutionarily conserved but highly recombinogenic. Proc Natl Acad Sci U S A 2003;100:14988-93.
42. Hu B, Han Sy, Wang X, et al. Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHK1 Pathway. J Cell Physiol 2005;202:518-23.
43. Milner AE, Levens JM, Gregory CD. Flow cytometric methods of analyzing apoptotic cells. Methods Mol Biol 1998;80:347-54.
44. Ishii H, Vecchione A, Murakumo Y, et al. FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proc Natl Acad Sci U S A 2001;98:10374-9.
45. Ausubel FM, Brent R, Kingston RE, et al. Current Protocols in Molecular Biology. New York: Wiley-Interscience; 1989.